Shandong Weigao Group Medical Polymer Company Limited (Weigao Group) repurchased 0.69 million H shares on 28 May 2026 via on-market transactions on the Hong Kong Stock Exchange, paying a total of HKD 2.29 million. The shares were bought at prices ranging from HKD 3.27 to HKD 3.38, translating into a volume-weighted average cost of HKD 3.323 per share.

Following the transaction, Weigao Group’s issued share capital (excluding treasury shares) fell from 4.47 billion to 4.47 billion shares, a reduction of 0.02%. Treasury shares increased to 57.33 million.

The buyback forms part of the mandate approved on 27 May 2025, which permits the company to repurchase up to 451.56 million shares (11.22% of shares outstanding at the time of approval). Cumulative repurchases under this authority have reached 50.68 million shares. In accordance with Hong Kong listing rules, Weigao Group is restricted from issuing new shares or selling treasury shares until 28 June 2026.